



ASX ANNOUNCEMENT

2 July 2020

**Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

Dear Sir / Madam,

Notification under sections 708A(5)(e) and (6) of the Corporations Act 2001 (Cth)

CardieX has issued an Appendix 3B and Appendix 2A with respect to the issue of 1,158,802 ordinary shares (CDX) of the Company. These were shares issued in lieu of cash payment for fees rendered to the equivalent of US\$17,500 (AU\$26,652) in CDX shares.

Details of the issue of shares are set out in the Appendix 3B and Appendix 2A lodged on the same day.

CardieX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the issue, CardieX has issued 1,158,802 ordinary shares (CDX) at the issue price of \$0.023 per share without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. As at the date of this notice:
 - (a) CardieX has complied with the provisions of Chapter 2M of the Act;
 - (b) CardieX has complied with section 674 of the Act; and
 - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

ENDS.

Authorised for release by:

**Jarrold White
Director**

For more information please contact:

**Investor Relations
Peter Taylor peter@nwrcommunications.com.au**



About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device (developed & marketed by 100% subsidiary ATCOR) is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.